Michael S. Saag

Mar 1, 2024 | jamanetwork.com | Paul E. Sax |Melanie Thompson |Michael S. Saag

To the Editor Long-acting injectable cabotegravir and rilpivirine (CAB-RPV) is approved for people with HIV who have viral suppression with oral antiretroviral therapy (ART), no known or suspected resistance to either drug, and no chronic hepatitis B. In clinical trials, switching to this injectable therapy demonstrated noninferiority to continued oral ART in maintaining viral suppression.

Jun 13, 2023 | medscape.com | Michael S. Saag |Roger Bedimo

closePlease confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log outCancel This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Michael S. Saag, MD: Hello.

Apr 11, 2023 | medscape.com | Michael S. Saag |Monica Gandhi

closePlease confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log outCancel This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Michael S. Saag, MD: Hello.